Upon activation, this receptor triggers NK cell degranulation, culminating in the release of cytolytic agents like perforins and granzymes, which are crucial for the lysis of target cancer cells.34–40 Combining an anti-CD16 nanobody and pHLIP (VHH-pHLIP) is expected to enhance the immune system’s ability to recognize and destroy cancer cells, potentially offering a breakthrough in cancer treatment. Here, PRF1 is linked to cancer.